logo

For the Inventor, By the Inventor

Waltham, MA, United States of America

Deciphera Pharmaceuticals, LLC

USPTO Granted Patents = 99

% Expired Patents = 19.2



Trademarks = 2

Forward Citations = 2,831

Loading Chart...
Loading Chart...

47 inventors (with patents filed for the assignee):

goldMedal Daniel L Flynn (52 out of 131 patents)

silverMedal Michael D Kaufman (49 out of 53 patents)

bronzeMedal Rodrigo Ruiz Soto (22 out of 22 patents)

4.  Scott Bone (21 out of 25 patents)

5.  Corey Bloom (21 out of 34 patents)

6.  Fred Jordan (21 out of 23 patents)

7.  Peter Albert Petillo (18 out of 28 patents)

8.  Oliver Rosen (17 out of 17 patents)

9.  Jama Pitman (17 out of 17 patents)

10.  Lakshminarayana Vogeti (13 out of 21 patents)

11.  Bryan D Smith (12 out of 14 patents)

12.  Timothy Malcolm Caldwell (11 out of 11 patents)

13.  Yu Mi Ahn (9 out of 9 patents)

14.  William C Patt (6 out of 8 patents)

15.  Keisuke Kuida (5 out of 5 patents)


Core Competencies:
CSF-1R Inhibitors
Combination Therapy
Gastrointestinal Stromal Tumors
Kinase Inhibitors
Vimseltinib
Autophagy Inhibitors
VPS34 Inhibitors
Raf Inhibitors
Aminopyrimidine Amides
Phenylaminopyrimidine Amides
Dihydronaphthyridines
N-acyl-N'-(pyridin-2-yl) Ureas

99 patents:

1. 12708617 - AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF (2026-08-18),
2. 12691108 - METHODS FOR TREATING VASCULAR MALFORMATIONS (2026-07-28),
3. 12686672 - CSF-1R inhibitors and methods of use thereof (2026-07-21),
4. 12643883 - Solid state forms of a kinase inhibitor (2026-06-02),
5. 12617775 - Processes of making CSF-1R inhibitors and methods of use thereof (2026-05-05),
6. 12616683 - Combination therapy for the treatment of gastrointestinal stromal tumors (2026-05-05),
7. 12582655 - METHODS OF TREATING DISORDERS USING CSF1R INHIBITORS (2026-03-24),
8. 12577249 - GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF (2026-03-17),
9. 12551483 - Formulations of vimseltinib (2026-02-17),
10. 12528787 - Solid state forms of a kinase inhibitor (2026-01-20),
11. 12509456 - Solid state forms of ripretinib (2025-12-30),
12. 12509443 - CSF-1R inhibitors and methods of use thereof (2025-12-30),
13. 12485120 - METHODS OF TREATING DISORDERS USING CSF1R INHIBITORS (2025-12-02),
14. 12479833 - HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF (2025-11-25),
15. 12447149 - Formulations of vimseltinib (2025-10-21),
Company Overview
Deciphera Pharmaceuticals, based in Waltham, MA, specializes in the development of innovative kinase inhibitors aimed at treating various cancers. The company focuses on advancing therapies for gastrointestinal stromal tumors and other malignancies through its proprietary technologies, including CSF-1R inhibitors and autophagy inhibitors. Deciphera's commitment to combination therapy strategies enhances the potential efficacy of its treatments, positioning the company as a leader in targeted cancer therapies.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

99 Patents

#17 in Waltham, MA

#211 in Massachusetts

#3,828 in US

#7,857 in the World

Waltham, MA (US)
Waltham, MA, United States of America

Deciphera Pharmaceuticals, LLC

Forward Citations = 2,831

47 inventors:

goldMedal Daniel L Flynn (52 out of 131 patents)

silverMedal Michael D Kaufman (49 out of 53 patents)

bronzeMedal Rodrigo Ruiz Soto (22 out of 22 patents)

4.  Scott Bone (21 out of 25 patents)

5.  Corey Bloom (21 out of 34 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Deciphera Pharmaceuticals, LLC. Retrieved from https://idiyas.com/company/deciphera-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…